アブストラクト
| Title | GLP-1受容体作動薬の注射剤と経口剤の相違点と使い分け |
|---|---|
| Subtitle | 特集1 アウトカムを意識した SGLT2阻害薬・インクレチン関連薬の使い方 インクレチン関連薬の多面的作用 |
| Authors | 小出祐也*1,2, 窪田創大*1,3, 加藤丈博*1, 矢部大介*1,3,4,5 |
| Authors (kana) | |
| Organization | *1岐阜大学大学院医学系研究科糖尿病・内分泌代謝内科学 / 膠原病・免疫内科学, *2松波総合病院総合内科, *3関西電力医学研究所糖尿病研究センター, *4岐阜大学高等研究院One Medicineトランスレーショナルリサーチセンター, *5東海国立大学機構健康医療データ統合研究教育拠点 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 1 |
| Page | 53-57 |
| Year/Month | 2023 / 1 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | 「Key Point」●GLP-1受容体作動薬は長時間作用型と短時間作用型に大別され, 血糖改善のメカニズムが異なる. ●長時間作用型の血糖改善は残存する膵β細胞機能に依存するため, 早期に導入するほど効果が大きいとされる. ●GLP-1受容体作動薬は低分子量と高分子量に大別され, 低分子量は減量効果が大きいとされる. ●注射剤に比して経口剤を希望される場合が多いが, 経口剤が十分に効果を発揮するには服薬指導が重要である. ●注射剤・経口剤に対する嗜好や費用などについて情報共有し, 治療法を一緒に考える. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Kuwata H, et al:Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes:A prospective, observational study. J Diabetes Investig, 12:2162-2171, 2021
- 2) Yabe D, et al:Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes. Expert Rev Endocrinol Metab, 9:659-670, 2014
- 3) Usui R, et al:Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes:association of remaining β-cell function and achievement of HbA1c target one year after initiation. J Diabetes Complications, 29:1203-1210, 2015
- 4) Usui R, et al:Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients:the association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation. J Diabetes Investug, 9:822-830, 2018
- 5) Yabe D, et al:Efficacy of Lixisenatide in patients with type 2 diabetes:a post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials. J Diabetes Complications, 30:1385-1392, 2016
残りの9件を表示する
- 6) Madsbad S:Review of head-to head comparisons of glucagonlike peptide-1 receptor agonists. Diabetes Obes Metab, 18: 317-332, 2016
- 7) Gabery S:Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight, 5:e133429, 2020
- 8) Pratley RE, et al:Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes(SUSTAIN 7):a randomized, open-label, phase3b trial. Lancet Diabetes Endocrinol, 6:275-286, 2018
- 9) Pratley RE, et al:Once-weekly albiglutide versus oncedaily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs(HARMONY 7):a randomized, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol, 2:289-297, 2014
- 10) Buckley ST, et al:Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med, 10:eaar7047, 2018
- 11) Rasmussen MF:The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes. Diabetol Int, 11:76-86, 2020
- 12) Yamada Y, et al:Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes(PIONEER 9):a 52-week, phase 2/3a, randomized, controlled trial. Lancet Diabetes Endocrinol, 8:377-391, 2020
- 13) Yabe D, et al:Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10):an open-label, randomized, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol, 8:392-406, 2020
- 14) Overgaard RV, et al:Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. Cell Rep Med, 2:100387, 2021
